Next Science Limited (ASX:NXS)
0.1400
0.00 (0.00%)
Dec 9, 2025, 10:08 AM AEST
Next Science Revenue
Next Science had revenue of $10.49M USD in the half year ending June 30, 2025, with 3.74% growth. This brings the company's revenue in the last twelve months to $22.07M, down -5.31% year-over-year. In the year 2024, Next Science had annual revenue of $22.82M with 2.87% growth.
Revenue (ttm)
$22.07M
Revenue Growth
-5.31%
P/S Ratio
1.22
Revenue / Employee
n/a
Employees
n/a
Market Cap
40.97M AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22.82M | 636.94K | 2.87% |
| Dec 31, 2023 | 22.18M | 10.47M | 89.36% |
| Dec 31, 2022 | 11.71M | 2.77M | 30.90% |
| Dec 31, 2021 | 8.95M | 5.51M | 160.03% |
| Dec 31, 2020 | 3.44M | -619.83K | -15.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Ramsay Health Care | 17.79B |
| Sonic Healthcare | 9.65B |
| Ansell | 3.06B |
| Cochlear | 2.34B |
| Regis Healthcare | 1.16B |
| Telix Pharmaceuticals | 1.01B |
| Neuren Pharmaceuticals | 218.86M |